Lets start a thread for comparing and contrasting Astex Pharmaceuticals to Synta. I'm curious what others think of the two companies. They both both have HSP90 inhibitors in development and both companies share similar market cap.
Owed ASTX for a number of years. Finally got paid for my patience this year. Was lucky enough to get out at $6.60 earlier this year. Sold because I thought the stock and market in general was getting a bit frothy. Can't believe that it has retraced back to $4.50 level. Their SGI-110 drug has the potential to be a monster as a replacement for their current approved drug Dacogen. AT 13387 looks interesting. The company really has put its efforts behind these 2 drugs. Love the rest of its pipeline as they have 5 partnered drugs. Of those like LEE-011. They plan on filing a new IND in q4 of this year. Going to get back in soon as to me, the story has not changed since the day I got out.
I agree I like SGI-110 as its an oral hypomethylating agent that will be a direct competitor to Celgene's CC-486 which an oral version of azacitidine. I spoke to Dr Mahadevan at ASCO about their Hsp90i and he spoke very highly of it. He conducted some of the initial phase I work. He mentioned that while they are seeing some retinopathy it is very low and transient and importantly reversible. I also like how they are clinically moving forward with their Hsp90i.
I'm digging more into ASTX but so far I think this is worthwhile speculative biotech. It's nice they have a revenue stream with Dacogen.